Hubei Biocause Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 000627.SZ

Hubei Biocause Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) on January 14, 2025: 0.88

Hubei Biocause Pharmaceutical Co., Ltd. Price to Book Ratio (P/B) is 0.88 on January 14, 2025, a 34.58% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Hubei Biocause Pharmaceutical Co., Ltd. 52-week high Price to Book Ratio (P/B) is 1.23 on December 16, 2024, which is 40.04% above the current Price to Book Ratio (P/B).
Hubei Biocause Pharmaceutical Co., Ltd. 52-week low Price to Book Ratio (P/B) is 0.38 on July 10, 2024, which is -56.17% below the current Price to Book Ratio (P/B).
Hubei Biocause Pharmaceutical Co., Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 0.66.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Shenzhen Stock Exchange: 000627.SZ

Hubei Biocause Pharmaceutical Co., Ltd.

CEO	Ms. Wenxia Zhou
IPO Date	Nov. 12, 1996
Location	China
Headquarters	#122 Yangwan Road
Employees	1,765
Sector	Health Care
Industries Pharmaceuticals

Description

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China.

Key trends

Past 5 years